Guidelines on treatment of epilepsy Review article
Article Sidebar
Main Article Content
Abstract
Treatment of epilepsy requires customization and adaptation to the needs of an individual patient. It seems that among the necessary changes to the guidelines on the treatment of epilepsy in Poland, supplementation of first-line treatment with newer generation medications should be recommended. It is also necessary to create defined lines of therapy to replace the concept of drug resistant epilepsy, the definition of which is still doubtful. Such changes are likely to result in a significant improvement in standards of epilepsy patient care.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Steinborn B (red.). Leczenie padaczki u dzieci i młodzieży. Termedia, Poznań 2011.
3. Guerreiro CA. Guidelines for drug treatment of epilepsy: a critical review. Arq Neuropsiquiatr 2008; 66(3A): 591-599.
4. Stern JM. Overview of evaluation and treatment guidelines for epilepsy. Curr Treat Options Neurol 2009; 11(4): 273-284.
5. Glauser T, Ben-Menachem E, Bourgeois B et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006; 47(7): 1094-1120.
6. Alderson P, Kosky N, Cross H. NICE response to World Report on epilepsy guidance. Lancet 2012; 379(9823): 1300.
7. Holmes D. NICE epilepsy guidance “may be detrimental to patient care”. Lancet 2012; 379(9814): 399.
8. Nunes VD, Sawyer L, Neilson J et al. Diagnosis and management of the epilepsies in adults and children: summary of updated NICE guidance. BMJ 2012; 344: e281.
9. Mazurkiewicz-Bełdzińska M. Co to są rekomendacje i komu służą z punktu widzenia klinicysty? Epileptologia 2012; supl 1: 34.
10. Brazdil M, Burešova J, Dolansky J et al. Soubor minimalnich diagnostickych a terapeutickych standardů u pacientů s epilepsii. EpiStop 2010.
11. Az emelt, kiemelt indikációhoz kötött támogatási kategóriába tartozó betegségcsoportok, indikációs területek és a felírásra jogosultak köre 2011 [online: www.oep.hu/gyogyszer].
12. Diener HC, Putzki N. Leitlinien für die Diagnostik und Therapie in der Neurologie, Georg Thieme Verlag, 4. überarb. Auflage 2008.
13. Hamer HM, Dodel R, Strzelczyk A et al. Prevalence, utilization, and costs of antiepileptic drugs for epilepsy in Germany – a nationwide population-based study in children and adults. J Neurol 2012; 259(11): 2376-2384.
14. Chadwick D, Marson T. Choosing a first drug treatment for epilepsy after SANAD: randomized controlled trials, systematic reviews, guidelines and treating patients. Epilepsia 2007; 48(7): 1259-1263.